Dimensional Fund Advisors LP Cuts Holdings in Health Catalyst, Inc. (NASDAQ:HCAT)

Dimensional Fund Advisors LP decreased its position in shares of Health Catalyst, Inc. (NASDAQ:HCAT) by 14.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,400,437 shares of the company’s stock after selling 228,756 shares during the period. Dimensional Fund Advisors LP’s holdings in Health Catalyst were worth $8,948,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in HCAT. Kennedy Capital Management LLC purchased a new position in shares of Health Catalyst during the first quarter valued at about $8,780,000. Essex Investment Management Co. LLC purchased a new position in shares of Health Catalyst during the first quarter valued at about $1,848,000. ClariVest Asset Management LLC grew its position in Health Catalyst by 303.9% in the first quarter. ClariVest Asset Management LLC now owns 282,325 shares of the company’s stock worth $2,126,000 after acquiring an additional 212,425 shares in the last quarter. Acadian Asset Management LLC grew its position in Health Catalyst by 38.3% in the first quarter. Acadian Asset Management LLC now owns 724,560 shares of the company’s stock worth $5,453,000 after acquiring an additional 200,494 shares in the last quarter. Finally, Los Angeles Capital Management LLC grew its position in Health Catalyst by 276.3% in the second quarter. Los Angeles Capital Management LLC now owns 213,693 shares of the company’s stock worth $1,365,000 after acquiring an additional 156,908 shares in the last quarter. Hedge funds and other institutional investors own 85.00% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on HCAT shares. Piper Sandler dropped their price target on Health Catalyst from $14.00 to $11.00 and set an “overweight” rating for the company in a research report on Monday, August 26th. Evercore ISI dropped their price target on Health Catalyst from $9.00 to $8.00 and set an “outperform” rating for the company in a research report on Tuesday, July 9th. JPMorgan Chase & Co. lifted their price target on Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 4th. Stephens dropped their price target on Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating for the company in a research report on Thursday, August 8th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $16.00 price target on shares of Health Catalyst in a research report on Friday. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, Health Catalyst currently has an average rating of “Moderate Buy” and an average price target of $11.42.

Health Catalyst Price Performance

Shares of HCAT opened at $7.62 on Tuesday. The firm has a market capitalization of $449.85 million, a PE ratio of -4.12 and a beta of 1.32. Health Catalyst, Inc. has a 1-year low of $5.42 and a 1-year high of $11.41. The company’s fifty day moving average price is $7.43 and its 200-day moving average price is $6.89.

Health Catalyst (NASDAQ:HCAT) last posted its quarterly earnings results on Wednesday, August 7th. The company reported $0.12 EPS for the quarter, beating the consensus estimate of $0.08 by $0.04. Health Catalyst had a negative net margin of 28.87% and a negative return on equity of 9.38%. The company had revenue of $75.90 million for the quarter, compared to analyst estimates of $74.96 million. During the same period in the prior year, the company earned ($0.21) earnings per share. The firm’s revenue was up 3.7% on a year-over-year basis. As a group, research analysts anticipate that Health Catalyst, Inc. will post -0.35 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, COO Daniel Lesueur sold 8,137 shares of the company’s stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $7.58, for a total transaction of $61,678.46. Following the completion of the transaction, the chief operating officer now owns 140,108 shares in the company, valued at $1,062,018.64. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, COO Daniel Lesueur sold 8,137 shares of the company’s stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $7.58, for a total transaction of $61,678.46. Following the completion of the transaction, the chief operating officer now owns 140,108 shares in the company, valued at $1,062,018.64. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Kevin Lee Freeman sold 7,500 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $7.22, for a total transaction of $54,150.00. Following the transaction, the insider now owns 255,881 shares of the company’s stock, valued at approximately $1,847,460.82. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 30,153 shares of company stock worth $216,004. Company insiders own 2.70% of the company’s stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.